The role of B cells in heart failure and implications for future immunomodulatory treatment strategies
Academic Article in Scopus
-
- Overview
-
- Identity
-
- Additional document info
-
- View All
-
Overview
abstract
-
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.Despite numerous demonstrations that the immune system is activated in heart failure, negatively affecting patients' outcomes, no definitive treatment strategy exists directed to modulate the immune system. In this review, we present the evidence that B cells contribute to the development of hypertrophy, inflammation, and maladaptive tissue remodelling. B cells produce antibodies that interfere with cardiomyocyte function, which culminates as the result of recruitment and activation of a variety of innate and structural cell populations, including neutrophils, macrophages, fibroblasts, and T cells. As B cells appear as active players in heart failure, we propose here novel immunomodulatory therapeutic strategies that target B cells and their products.
status
publication date
published in
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional document info
has global citation frequency
start page
end page
volume